Clinical trials: Schizophrenia
Schizophrenia
Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
The purpose of this study was to evaluate the efficacy and safety of elpipodect at a range of doses (8 mg, 16 mg, and 24 mg once daily [QD]) in adult participants who have an acute episode of schizophrenia according to Diagnostic…
- Trial name
- NCT04624243
- Testing
- Elpipodect, Risperidone
- Where
- 121 sites in United States, Bulgaria and 10 more
- Volunteers
- 499 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Aripiprazole Once-monthly in Patients With Schizophrenia
To obtain information on the safety, tolerability and effectiveness of aripiprazole once-monthly in a manner consistent with its intended use in everyday clinical practice in patients with schizophrenia who completed Study 14724A…
- Trial name
- NCT01959035
- Testing
- Aripiprazole once-monthly
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia
The purpose of this study is to evaluate the effectiveness of paliperidone ER for the treatment of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and…
- Trial name
- NCT01577160
- Testing
- Paliperidone ER
- Volunteers
- 353 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Schizophrenic Disorders, Schizoaffective Disorder
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot.
- Trial name
- NCT00088465
- Testing
- Intramuscular olanzapine depot
- Where
- 92 sites in United States, Argentina and 23 more
- Volunteers
- 931 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Mania
A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis
To assess the efficacy, safety, and tolerability of intramuscular ziprasidone in the treatment of the acute exacerbation of non-organic psychosis of any etiology, including schizophrenia, acute mania, delusional disorder and…
- Conditions
- Schizophrenia, Mania, Delusional Disorder, Acute Exacerbation of Psychosis
- Trial name
- NCT00644800
- Testing
- Ziprasidone
- Where
- 8 sites in Brazil
- Volunteers
- 89 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia
The purpose of this study is to evaluate the tolerability and safety of Lu AF35700 after repeated oral dosing to patients with schizophrenia.
- Trial name
- NCT02202226
- Testing
- Lu AF35700
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
A Study of the Dose Proportionality of Extended Release Paliperidone
The purposes of this study are to evaluate the dose proportionality of 1.5- and 3 mg tablets of paliperidone ER, to document the pharmacokinetics of a 1.5 mg dose of paliperidone ER, and to assess the safety and tolerability of…
- Trial name
- NCT00791167
- Testing
- Paliperidone ER
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia
This is a Phase Ib clinical study of TPN672 maleate in patients with schizophrenia
- Trial name
- TPN672 (NCT05192304)
- Testing
- TPN-672
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
Schizophrenia
A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone
The purposes of this study are to estimate the relationship of D2-receptor occupancy to plasma concentration and to assess the safety of OROS paliperidone.
- Trial name
- NCT00796432
- Testing
- OROS paliperidone
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Negative Symptoms of Schizophrenia
Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
MIN-101C07 is a multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of roluperidone in adult schizophrenia patients.The primary objective is to…
- Trial name
- NCT03397134
- Testing
- Roluperidone 32 mg, Roluperidone 64 mg
- Where
- 39 sites in United States, Bulgaria and 2 more
- Volunteers
- 515 people
- Sponsor
- Minerva Neurosciences
Schizophrenia
Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with a primary diagnosis of schizophrenia according to criteria of the Diagnostic and Statistical Manual of…
- Trial name
- NCT04959032
- Testing
- Lumateperone 42 mg
- Where
- 43 sites in United States, Bulgaria and 2 more
- Volunteers
- 592 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia
A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia
To evaluate the safety of SEP-363856 (75 mg/day or 100 mg/day) administered for 52 weeks in adult participants with schizophrenia
- Trial name
- NCT07225712
- Testing
- SEP-363856
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Creating Live Interactions to Mitigate Barriers
This study is a validation study to evaluate the acceptability, feasibility and impact of a mobile psychosocial intervention to enhance social functioning in people with schizophrenia.
- Trial name
- CLIMB (NCT03317769)
- Testing
- Computerized Plasticity-Based Adaptive Cognitive Training, Commercially available computerized training, Optimized social skills training
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Posit Science Corporation
Schizophrenia
A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose
The purposes of this study are to investigate the metabolic pathways of paliperidone and excretion of paliperidone and its metabolites in healthy adult male volunteers, both CYP2D6 poor and extensive metabolizers, after…
- Trial name
- NCT00796029
- Testing
- 14C-paliperidone
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo
This study is being carried out to see if quetiapine (Seroquel) is effective in preventing patients from a schizophrenic relapse when studied for a long time (1 year) and if so, how it compares with non-active treatment.
- Trial name
- NCT00228462
- Testing
- Seroquel (quetiapine)
- Where
- 5 sites in Bulgaria, Poland
- Volunteers
- 197 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
The purpose of this study is to evaluate the efficacy and safety of ziprasidone in acute exacerbation of schizophrenia or schizoaffective disorder, including patients with recent onset of symptoms
- Trial name
- NCT00645229
- Testing
- Ziprasidone
- Where
- Portugal
- Volunteers
- 1 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizoaffective Disorder
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
Lyndra Therapeutics, Inc. is developing LYN-005, a long-acting oral (LAO) capsule (LYNX™ dosage form) of risperidone. This pivotal study (LYN-005-C-301) will evaluate the PK as well as safety and tolerability of multiple…
- Trial name
- NCT05779241
- Testing
- LYN-005, Risperidone
- Where
- 5 sites in United States
- Volunteers
- 83 people
- Sponsor
- Lyndra Inc.
Schizophrenia
Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia
The purpose of this study is to evaluate efficacy, safety and tolerability of flexible, once-daily doses of paliperidone extended-release (ER) in patients with schizophrenia from Argentina and Colombia that previously failed…
- Trial name
- PERFLEX (NCT01724359)
- Testing
- Paliperidone ER
- Where
- 5 sites in Argentina, Colombia
- Volunteers
- 95 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia
Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia
The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate injection compared to placebo in the treatment of the symptoms of schizophrenia in adults.
- Trial name
- NCT00074477
- Testing
- R092670
- Volunteers
- 250 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
The purpose of this study is to assess the long-term symptomatic response (Visit 2 [Week 1] to Visit 14/Week 66 [End of Study {EOS}]) measured by change in the Clinical Global Impressions -Severity for Schizophrenia (CGI-SS) in…
- Trial name
- CASPAR (NCT04940039)
- Testing
- Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., Paliperidone Palmitate 75 mg eq.
- Where
- 5 sites in Rwanda
- Volunteers
- 93 people
- Sponsor
- Janssen-Cilag International NV
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.